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Two birds with one stone: possible
dual-role of oxytocin in the treatment
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Oxytocin (OT), a hormone most commonly associated with labor and lactation, may
have a wide variety of physiological and pathological functions, which makes OT and
its receptor potential targets for drug therapy. In this review, we highlight the newly
discovered metabolic role of OT in diabetes and its complication, such as diabetic
osteopathy. OT may have positive metabolic effects; this is based on the change in
glucose metabolism, lipid profile, and insulin sensitivity. It may modify glucose uptake and
insulin sensitivity both through direct and indirect effects. It may also cause regenerative
changes in diabetic pancreatic islet cells. Moreover, it has an anabolic effect on the bone
biology. So, the activation of the OT receptor pathway by infusion of OT, OT analogs, or
OT agonists may represent a promising approach for the treatment of diabetes and some
of its complications, including diabetic osteopathy.
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Introduction
The story of oxytocin (OT) begins right before labor, continues during birth, and later during the
early period of lactation. Several physiological and pathological functions are governed directly or
indirectly by OT (1, 2). This makes OT, and its receptor, potential targets for drug therapy. The
therapeutic use of the OT is limited to, initiate labor and milk ejection (1, 2). However, there are
indications that show a significant role of OT away from pregnancy (1, 2). OT is considered as a
cardiovascular hormone with cardio-protective effects under experimental conditions (3). It has
been shown that cardiovascular dysfunctions are related to metabolic disorders, such as obesity,
insulin resistance, and diabetes (4).
Diabetes is one of the metabolic disorders considered as one of the major causes of mortality
worldwide. Its incidence is expected to increase dramatically over the coming decades (5). It is char-
acterized by a chain of complications that affect many organs. Osteoporosis (diabetic osteopathy) is
one of these complications (6). Many endogenous and exogenous factors, more or less dependent
on each other, are known to influence energy metabolism and bone mass accumulation. OT is one
of these endogenous factors. Several lines of evidence have largely demonstrated that OT has many
positive metabolic effects; this is based on a remarkable change in glucose metabolism, lipid profile,
and insulin sensitivity after OT administration (7–10). In addition, it has also an anabolic effect on
bone metabolism (11–13).
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Metabolic Effect of OT
Feeding behavior, body weight, and energy balance are crucially
regulated by the hypothalamus in the CNS (14). Several stud-
ies have linked OT to the hypothalamus–brainstem circuits that
negatively regulate feeding (15–17). However, the physiological
relevance and pathological relevance of OT were unexplored until
researchers found that obesity linked to OT release defect, andOT
treatment was able to effectively correct overeating and obesity
(8–10). Deficits in OT or its receptor developed hyperleptinemia
and late-onset obesity with increases in abdominal fats and fasting
plasma triglycerides (TGs) (18, 19).
Oxytocin has a role in affecting glucose and insulin home-
ostasis, as well as regulating body weight balance. It has been
reported that OT promotes glucose uptake (20, 21) and stimulates
insulin secretion (22–26). It stimulated insulin secretion in pan-
creatic islets independently of plasma glucose changes while it also
stimulated pancreatic glucagon secretion (25). This might suggest
the involvement of OT in pathophysiology of diabetes. Recent
research demonstrated that OT administration reduced obesity-
related diabetic changes, such as glucose intolerance, insulin resis-
tance, and pancreatic islet hypertrophy (7–10, 27, 28). Two weeks
treatment with OT decreased adiposity and food intake in obese
mice lacking leptin, although it worsen glucose metabolism, most
likely due to an increase in corticosterone levels and enhanced
hepatic glucose production. It could be suggested that the effect of
OT in decreasing fatmass is independent of leptin, while the bene-
ficial impact on glucosemetabolism requires the presence of leptin
(29). Whereas, OT treatment for longer period, notably reduced
body fat accumulation, fasting blood glucose levels, and improved
insulin sensitivity and glucose tolerance in leptin receptor defi-
cient mice (30). The hypoglycemic effect, stimulatory effect on
insulin secretion and sensitivity, and improvement of pancreatic
islet cells after OT administration, strongly suggested that OT
might be a therapeutic target for treating diabetes.
Role of Oxytocin Signaling on Glucose and
Lipid Metabolism
Coupling of Oxytocin Receptors to Intracellular
Cascades
Oxytocin receptor (OTR) is known to be present in neurons.
This receptor is also present in other tissues like adipose tissue
and pancreas (31). OT receptor is a G protein-coupled receptor
(GPCR), which linked through G
αq/11 to phospholipase C (PLC)
(32). Activation of PLC causes an increase in inositol trispho-
sphate (IP3) and diacyl glycerol (DAG). IP3 activates specific
receptors in the sarcoplasmic reticulum in order to release Ca2+
into the cytosol to form a complex with calmodulin. This activates
myosin light chain (MCL) kinase to phosphorylate MLCs causing
myocyte contraction (33). DAG induces protein kinase C (PKC)
activation, which has been implicated in uterine contraction. OT
receptor activation leads to an increase in prostaglandin produc-
tion through phospholipase A2 and cyclooxygenase-2. The MAP-
kinase (MAPK) cascade is activated by different pathways like
trans-activation of receptor tyrosine kinases and also by possibly
different G protein-linked pathways (34). In fact, the coupling of
theOTR toGs andGi proteins is also occurring. The trophic effect
of OT is occurring via a PKC-mediated activation of eukaryotic
elongation factor-2 (35). In different cell systems, the multiple
signaling pathways are activated by OTRs, which may act syn-
ergistically like contraction of myometrial cells that induced by
OTR coupling to G
αq-11 and to the small G proteins of the Rho
pathway (36). However, they may also have an opposite effect
on the same cell function, such as the proliferative effects of OT,
which appear to beGq-linked and involveMAPK activationwhich
leads to c-fos and c-jun induction. On the other hand, inhibition
of cell growth has been reported to be Gi mediated (37). Due
to this heterogeneity in the final outcome, functional selective
ligands would be of great importance in identifying the roles of
the different OTR-elicited pathways in physiological functions.
Arginine-vasopressin (AVP) is another posterior pituitary hor-
mone, which differ from OT only by two amino acids. AVP
and OT trigger their effects through at least four subtypes of
receptors (V1a, V1b, V2, and OT receptors). V1a receptors mediate
glycogenolysis and vasoconstriction, Vlb receptors mediate the
release of adrenocorticotropic hormone (ACTH), catecholamine,
insulin, and glucagon, and V2 receptors mediate antidiuresis (38).
Because OT andAVP share similar structures, it is not unexpected
that they cross-react with each other’s receptor. For instance,
AVP stimulates myometrial contraction via OTR (39) and OT
stimulates the release of ACTH through V1b (40). OT interacts
with AVP receptors with a lower affinity. It has been reported that
both OT and AVP induce insulin and glucagon release from the
pancreas by activating V1b receptors (41, 42).
Glucose and Insulin Homeostasis
Oxytocin can be a good choice to decrease the blood glucose
level and increase the insulin level. The hypoglycemic effect of
OT can be explained by increasing glucose uptake via insulin-like
signaling pathway (20, 21). The glucose uptake in cardiomyocytes
(CMs) is increased by OT through stimulation of intracellular
release of Ca2+, and also activation of phosphoinositide-3-kinase
(PI3K), calcium-calmodulin kinase kinase (Ca-CAMKK), and
AMP-activated protein kinase (AMPK) pathways (Figure 1) (20,
21). The hypoglycemic actions of OT are also believed to be
mediated indirectly through changes in pancreatic functions (25)
as OT modulates insulin secretion centrally via vagal cholinergic
neurons innervating β-cells andperipherally via phosphoinositide
turnover and activation of protein kinase-C in pancreatic β-cells
(Figure 1) (22–26).
Pancreatic islet inflammation is an important factor in the
pathogenesis of diabetes. The protection of β-cells from death is
considered as a new therapeutic target. This inflammatory pro-
cess is probably a combined consequence of dyslipidemia, hyper-
glycemia, and increased circulating proinflammatory cytokines
[leptin, interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor
necrosis factor-α (TNF-α) (43)]. OT decreases pancreatic islet
hypertrophy (7, 28). Yet, the remaining question is whether
OT directly promotes β-cell regeneration or it acts indirectly.
Unfortunately, the exact mechanism is still unknown and fur-
ther studies are needed. Whereas, the indirect effect(s) may be
related to its action as insulin sensitizers, with a reduction in
gluco- and lipotoxicity (7–10). As well as, OT has antioxidant and
anti-inflammatory effects (44–46).
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FIGURE 1 |Metabolic effects of oxytocin: OT is secreted from the
posterior lobe of the pituitary gland and binds to its receptor in
peripheral tissues. In adipose tissue, it induces fatty acid oxidation and
lipolysis, and formation of small adipocytes. Small adipocytes increase
secretion of adiponectin and decrease leptin secretion, which improve
insulin sensitivity in adipose tissue, liver, and muscles. In pancreas, it
induces insulin secretion via phosphoinositide (PI) turnover and activation
of protein kinase C, and regeneration of pancreatic β-cells. In liver and
muscles, it enhances glucose uptake by stimulation of intracellular release
of calcium, and activation of phosphoinositid-3-kinase (PI3K),
calcium-calmodulin kinase kinase (Ca-CAMKK), and AMP-activated protein
kinase (AMPK).
In addition to increasing insulin secretion, OT also improves
insulin sensitivity by both reducing gluco- and lipotoxicity (7–
10) and regulating cytokines like leptin and adiponectin (7, 9).
OT decreased fat mass, resulting in reduction in leptin level,
which could also be one of the reasons underlying theOT-induced
improvement in insulin sensitivity (9). However, the results of
adiponectin after OT administration are contradictory. In some
studies, adiponectin concentrationwas not affected byOT admin-
istration (30, 47), and in others, OT treatment induces an increase
in adiponectin level (7). OT treatment induced formation of small
adipocytes in treated rats as compared to control (47). It could be
the smaller adipocytes, which are more sensitive to insulin pro-
duce a lower amounts of leptin and higher amounts of adiponectin
(Figure 1). The balance of leptin and adiponectin in diabetic
patients can be used as a predictor of insulin resistance and a useful
indicator for the choice of drug to treat diabetes mellitus (48).
Lipid Metabolism
Oxytocin improves lipid profile of diabetic rodents as well by low-
ering serum low-density lipoprotein (LDL), TG, and cholesterol
levels, and a propensity for high-density lipoprotein (HDL) level
improvements (7). OT induces lipolysis and β-oxidation of fatty
acids (9, 10). The effects of OT on adipocytes are mediated either
directly by a mechanism via its peripheral effects on adipocytes,
or indirectly through the central anorectic action and centrally
mediated activation of sympathetic nerve innervating fat tissue.
Peripheral actions of the OT are mediated by OTR. OT receptor
mRNA is highly expressed in mouse adipocytes and increased
during the differentiation of adipocyte (49). The stimulatory
effect of OT on lipid metabolism is mediated by an increase
in the mRNA expression of lipoprotein lipase (Lpl) and fatty
acid transporter (Fat, also known as CD36). These two enzymes
are responsible for the uptake of circulating TG and fatty acids,
respectively. On the other hand, OT does not modify the mRNA
level of enzymes involved in lipogenesis and TG storage, such as
acetyl-coenzyme A carboxylase α (Acaca, also known as ACC-α),
fatty acid synthase (Fasn), and diacylglycerol O-acyltransferase
homolog 1 (Dgat1). OT also increases the mRNA levels of the
enzymes involved in the process of lipolysis, such as hormone-
sensitive lipase (Hsl) and patatin-like phospholipase domain con-
taining 2 (Pnpla2). The increase in lipolysis process andTGuptake
without a change in lipogenesis and TG storage under the effect
of OT shows that OT promotes the use of fat as energy substrate
(9). OT treatment induces formation of small adipocytes in treated
rats as compared to control (47). This adipogenic effect of OT
could be explained by the activation of peroxisome proliferator-
activated receptors-γ (PPARγ), a key regulator of adipocyte
differentiation (50).
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Anabolic Actions of OT on the Skeleton
One of the most important bone-research results has revealed
that the pituitary hormones have an intense outcome on bone
(51), so that the pituitary–bone axis turned into one of the most
important topics in skeletal physiology. Based on the fact that
calcium is mobilized from the maternal skeleton during lactation
and late pregnancy, it might be expected that the same hor-
mone that regulates parturition and lactation might also controls
skeletal homeostasis. Our research group and other scholars have
developed studies to find new bone formation therapies. As a
primitive neurohypophyseal hormone, OT has been reported to
be an anabolic bone mass regulator (11–13).
A specific and accurate method for measuring OT is urgently
needed for a better understanding of OT role, because the meth-
ods that are currently used to measure the peripheral OT level
lack reliability (52). Previous study reported that plasma levels
of OT are notably lower in postmenopausal women who develop
osteoporosis than in healthy peers (12). Changes in bone remod-
eling and osteopenia in ovariectomized (OVX) rodents resulted
in a significantly decreased OT level when it is compared with
sham-operated controls (53). Moreover, in genetically modified
animals, it was confirmed that deletion of OT or OTR causes a
remarkable reduction in bone formation and this suggested that
OT is crucial for basal skeletal homeostasis (13). Interestingly, it
has been found that OT treatment inmice increased bonemineral
density as well as osteoblast formation (11), it also reversed bone
loss in 8-week-old OVXmice, and reduced marrow adiposity (12,
13). Its positive bone balance suggests that OT could be used
therapeutically as an ally in the recovery of osteopathy resulting
from diabetes.
Role of Oxytocin Signaling on Bone
Metabolism
At the cellular level, OT stimulates differentiation of osteoblasts
to a mineralizing phenotype by up-regulating bone morphogenic
protein-2 (13). The effect of OT on osteoclasts was found to
be more complex as osteoclast formation was stimulated, while
bone resorption by mature osteoclasts was inhibited (7, 54). The
effect of OT on bone could be resulted from the direct interaction
of the hormone with its receptors in bone cells (54, 55). The
signaling cascades that mediate the OT action on bone cells even-
tually release of Ca2+ from intracellular stores and trigger MAPK
signaling (13). The increase in intracellular Ca2+ in osteoblasts
provokes cellular cascades, such as JNK, P38, extracellular signal
regulated kinase (ERK), PKA, and PI3K (56). This leads to an
increase in prostaglandin E2 synthesis, with subsequent positive
bone balance. OT and OTR interactions in osteoblast may also
provoke other intracellular events, such as MAP-kinase phos-
phorylation and induce c-Fos expression (Figure 2) (55). It has
been reported that OTR, on stimulation by its ligand OT, translo-
cates into the nucleus of osteoblasts (57). The passage of OTR
into the nucleus is facilitated by successive interactions with β-
arrestins (ARRBS), the small GTPase Rab5, importin-β (KPNB1),
and transportin-1 (TNPO1). This mechanism for OTR translo-
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FIGURE 2 | Oxytocin signaling in bone cells: OT binds to its receptor in
osteoclast (OC) and osteoblast (OB), and initiates several cellular
cascades. It induces OB differentiation by inducing c-fos expression and
MAP-kinase phosphorylation. OT induces release of Ca2+ from intracellular
stores. In OB, the increase in Ca2+ provokes several cellular cascades (JNK,
P38, ERK, PKA, and PI3K), which lead to an increase in prostaglandin E2
synthesis, with positive effects on OB. In OC, OT increases OC formation
directly, by activating MAPK signaling, and indirectly through the up-regulation
of RANK-L from OB. The increase in Ca2+ induces NF-kb and IP3 which
inhibit bone resorption of mature OC.
modulation by nuclear GPCRs (57). While in osteoclast, OT has
dual effects. It increases osteoclast formation both directly, by
activating nuclear factor-kβ and MAPK signaling, and indirectly
via the up-regulation of receptor activator of nuclear factor kappa-
B ligand (RANK-L) (Figure 2). The increase in osteoclastoge-
nesis is coupled to the decrease in bone resorption of mature
osteoclasts and this can be explained by triggering the cytoso-
lic Ca2+ release and nitric oxide synthesis (13, 54). This might
explain the significant decrease in the levels of TRAP, a bone-
resorption marker that observed after OT administration (7). In
addition to OTR, both AVP receptors, V1a and V2, are expressed
in osteoblasts and osteoclasts, and their stimulation induces ERK
activation, which in turn inhibits bone formation and stimulates
bone resorption. This coupling would lead to bone loss (58).
So, it could be concluded that the anabolic effects of OT on
bone are not occurring through activation of vasopressin receptor
signaling.
In addition to its direct effect, OT was found to have an
indirect effect on bone through its action on cytokines (leptin
and adiponectin) (7, 9) that have a considerable role in bone
biology. Leptin has two opposite effects on bone. Centrally, it
suppresses bone formation by restraining osteoblast proliferation.
Peripherally, it stimulates osteoblastic differentiation and inhibits
osteoclastogenesis. The two pathways could compensate each
other, with the peripheral and positive effects being the major
when leptin central resistance occurs with obesity onset (59).
Adiponectin stimulates the differentiation and mineralization of
osteoblasts and inhibits themacrophage colony-stimulating factor
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(M-CSF)- and RANKL-induced osteoclast differentiation, as well
as the bone-resorption activity of mature osteoclasts (60).
Exogenous Oxytocin Administration
Besides its use in obstetrics, it has been reported that OT could
play an important role in treating psychiatric disorders, such
as autism and schizophrenia (61, 62). The most precise and
reliable mode of delivering OT is through infusing it directly
into the blood. Orally administered OT, due to its peptide
structure, is rapidly degraded by proteolytic enzymes in the
gut. Plasma-delivered OT, such as an intravenous injection,
does not cross the blood–brain barrier. Intranasal OT is cur-
rently the favored administration method for neurobehavioral
research because of its absorption through the nasal mucosa.
Efficient brain penetration and activation of OTR are potentially
an important limitation to the current OT therapies. Yet, the
next generation of therapeutics may bypass this problem. Phar-
macologically enhancing endogenous OT release, or developing
small-molecule agonists and positive allosteric modulators, may
be more effective (2). Regarding therapeutic consequences, the
coupling of OTR to different G proteins exhibiting opposite
effects, renders the definition of “agonist” and “antagonist”
rather questionable. The ability to design compounds that can
discriminate between many pathways, and predominantly acti-
vate a specific intracellular reaction, will be at the heart of
future OTR-based drug strategies (2). Taking into considera-
tion a potential use of OT as a therapeutic agent, an important
issue to be addressed is the possible side effects of this treat-
ment. OT’s side effect profile appears relatively benign accord-
ing to recent studies focused on its effects on children and
adolescents. No severe side effects of any kind, metabolic, or
otherwise were reported (61, 62), but larger studies are still
needed.
Conclusion
These beneficial observations, which are discussed above, clearly
showed that OT and its analogs are involved in regulation of
metabolic and bone balance and are opening up a new window
for drug development in diabetes and osteoporosis therapeutics.
The potential therapeutic uses of OT and more long-acting and
specific analogs of OT are huge. As a short nine amino acid
peptide, OT is considered to be ideal for the design of agonists
and antagonists of its receptor. Continued studies are still needed
to develop new drugs including the use of OT, OT agonists, and
antagonists for various human disorders including diabetes and
osteoporosis.
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